Holmen says that utilizing targeted therapies could potentially be the answer, though clinically-tested combinations have historically not done as well as clinicians had hoped.
Sheri Holmen, PhD, associate professor, Department of Surgery, University of Utah School of Medicine, discusses options for treating brain metastases in melanoma. Holmen says that utilizing targeted therapies could potentially be the answer, though clinically-tested combinations have historically not done as well as clinicians had hoped. She adds that combinations are still on the table in terms of treating brain metastases in melanoma, both with other targeted therapies, as well as immunotherapies.
Atlas Examines Tolerability of Hedgehog Pathway Inhibitors and Transition to IO in mBCC
October 16th 2024During a Case-Based Roundtable® event, Jennifer L. Atlas, MD, discussed treatment for a patient with basal cell carcinoma who reported challenging adverse events with hedgehog pathway inhibitor.
Read More
RELATIVITY-047 vs CheckMate 067 Matched Cohorts in Melanoma Show Similar Efficacy
October 10th 2024During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.
Read More